２型糖尿病患者に対するグリメピリド１日１回投与による臨床効果

• 小林 正

  富山医科薬科大学医学部内科学第1

• 加来 浩平

  川崎医科大学内科学

• 河盛 隆造

  順天堂大学医学部内科学

• 岩本 安彦

  東京女子医科大学糖尿病センター

• 清野 裕

  京都大学大学院医学研究科/医学部糖尿病・栄養内科学

書誌事項

タイトル別名

• Improved Control with Once-Daily Administration of Glimepiride for OHA Naive and Oral Monotherapy Japanese Patients without Clinically Significant Weight Gain
• 2ガタ トウニョウビョウ カンジャ ニ タイスル グリメピリド 1ニチ 1カイ トウヨ ニ ヨル リンショウ コウカ

抄録

This prospective observational study evaluated the efficacy and safety of once-daily glimepiride monotherapy, together with the effect on body weight, for 6 months in Japanese Type 2 diabetic patients.Subjects were 1, 236 Japanese type 2 diabetes mellitus patients (mean age: 62.7±10.7years), recruited from 183 study sites across Japan.Patients who were oral hypoglycemic agent (OHA) naive numbered 30%, and 61% had been switched from previous mono or combination therapy with other oral hypoglycemic agents (OHA).HbA₁c improved significantly in the 293 OHA naive patients [median:(25%, 75%), 7.60:(7.10, 8.00)% to 6.50:(6.10, 7.00)%, p<0.0001], and a significant decrease in HbA1c was observed in patients switched from other oral monotherapy (nateglinide, α-GI, biguanide). In switching from other SU monotherapy to glimepiride, glycemic control improved significantly for patients with HbA₁c>7 prior to treatment, while patients with already good control (HbA1c≤7) maintained control.Similar trends in improvement were also observed in FPG.Glimepiride did not result in any clinically relevant weight gain.Although initiating glimepiride in OHA naive patients resulted in a median BMI increase of+0.28kg/m² [23.72:(21.77, 26.18) kg/m² to 24.00 (22.20, 26.37) kg/m², p<0.0001], no significant change in BMI was observed in subgroups previously treated with other OHA monotherapy (except nateglinide and α-GI).Adverse effects, including hypoglycemia, occurred in 8.54%(103/1206).This study confirmed that monotherapy with oncedaily administration of glimepiride is safe and improves glycemic control to a satisfactory level in OHA naive patients and in switching from most OHA monotherapy regimens.

収録刊行物

• 糖尿病

  糖尿病 47 (9), 727-735, 2004

  一般社団法人 日本糖尿病学会

キーワード

• 2型糖尿病
• 糖尿病治療薬 (血糖降下薬)
• コンプライアンス
• 血糖コントロール

詳細情報

• CRID: 1390001204904791040
• NII論文ID: 130004339053
• NII論文ID: 10014047219
• NII書誌ID: AN00166576
• DOI: 10.11213/tonyobyo1958.47.727
• ISSN: 1881588X
• ISSN: 0021437X
• NDL書誌ID: 025098183
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I025098183
• Web Site: https://search.jamas.or.jp/link/ui/2005040465
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • NDL
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可